Biohaven Pharmaceutical Holding Co Ltd (BHVN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biohaven Pharmaceutical Holding Co Ltd (BHVN) has a cash flow conversion efficiency ratio of -2.509x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-130.66 Million) by net assets ($52.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Biohaven Pharmaceutical Holding Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Biohaven Pharmaceutical Holding Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Biohaven Pharmaceutical Holding Co Ltd for a breakdown of total debt and financial obligations.
Biohaven Pharmaceutical Holding Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biohaven Pharmaceutical Holding Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mullen Group Ltd.
TO:MTL
|
0.052x |
|
Guangzhou Sanfu New Materials Technology Co. Ltd. A
SHG:688359
|
0.016x |
|
Guangdong Marubi Biotechnology Co
SHG:603983
|
0.013x |
|
NGL Energy Partners LP
NYSE:NGL
|
0.309x |
|
Fila Holdings Corp
KO:081660
|
0.099x |
|
Resilient Property Income Fund Ltd
JSE:RES
|
0.031x |
|
Faraday Technology Corp
TW:3035
|
-0.038x |
|
Henan Thinker Automation
SHG:603508
|
0.029x |
Annual Cash Flow Conversion Efficiency for Biohaven Pharmaceutical Holding Co Ltd (2017–2025)
The table below shows the annual cash flow conversion efficiency of Biohaven Pharmaceutical Holding Co Ltd from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Biohaven Pharmaceutical Holding Co Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $52.07 Million | $-609.44 Million | -11.704x | -750.85% |
| 2024-12-31 | $423.44 Million | $-582.45 Million | -1.376x | -77.47% |
| 2023-12-31 | $427.98 Million | $-331.73 Million | -0.775x | -40.28% |
| 2022-12-31 | $538.77 Million | $-297.69 Million | -0.553x | +64.13% |
| 2021-12-31 | $94.69 Million | $-145.84 Million | -1.540x | -55.69% |
| 2020-12-31 | $76.78 Million | $-75.96 Million | -0.989x | -101.95% |
| 2019-12-31 | $-7.42 Million | $-377.33 Million | 50.826x | +3990.94% |
| 2018-12-31 | $150.92 Million | $-197.14 Million | -1.306x | -81.82% |
| 2017-12-31 | $131.97 Million | $-94.81 Million | -0.718x | -- |
About Biohaven Pharmaceutical Holding Co Ltd
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase… Read more